Medical College of Wisconsin physicians who specialize in gynecologic cancers collaborate with researchers and academic medical centers around the country to advance the understanding and treatment of ovarian, cervical, uterine, vulvar and vaginal cancers. Their patients – and the entire region – are the direct beneficiaries of ongoing research.
The Gynecologic Cancer Program is an active member of the Gynecologic Oncology Group (GOG), an organization that coordinates multi-center clinical trials to advance the treatment of gynecologic cancers. The program is also involved with the Radiation Therapy Oncology Group (RTOG). Both are cooperative research groups funded by the National Cancer Institute.
Our physicians are also working to establish a Women’s Health Research Initiative and a tissue bank to advance the understanding of female cancers.
Ongoing studies provide access to the best research has to offer in advanced treatments and improved quality of life.
The following clinical trials are open to enrollment.
To obtain information regarding any gynecologic clinical trials that our department has open, please contact our research team at 1-855-771-9477 or Email Us.
|Type of Cancer||Protocol ID & Study Title|
|Cervical||Anti PD-L1 Atezolizumab)
Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
Keywords: Cervical Cancer, Atezolizumab, Cisplatin, Chemoradiotherapy, Node Positive, Anti PD-L1
A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Cervical Carcinoma
Keywords: Cervical cancer, recurrent , metastatic, LN-145, TILs
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Keywords: Randomized, Phase II, Cisplatin, Stage II-IVA
An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma.
Keywords: Recurrent Endometrial Cancer, Endometrial Carcinoma, Endometrial, Atezolizumab, Bevacizumab, Rucaparib
|Endometrial||Tesaro TSR-042 4010-01-001
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD1 Monoclonal Antibody in Patients with Advance Solid tumors
Keywords: Endometrial, Tesaro, TSR-042, Advanced, 4010-01-001, Phase 1, Anti-PD1 Monoclonal Antibody, Solid Tumors
|VIN 3/ HPV, Pre-cancer, HPV||INOVIO- HPV-201
A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA® 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva
Keywords: Pre-Cancer, Vulvar, VIN, HPV
|Ovarian||The OVAL Study
A Randomized, Controlled, Double-Arm, Double Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Other Study Identifiers: VB-111-701, GOG-3018
Keywords: Recurrent Ovarian Cancer, Platinum Resistant Ovarian Cancer, Ovarian, Ovarian Carcinoma, Epithelial Ovarian Cancer, Paclitaxel, VB-111, GOG-3018
|Ovarian||GOG-3020 / ENGOT-ov45/NCRI/ATHENA
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients.
Keywords: Ovarian, Parp, Rucaparib, ATHENA y, Nivolumab, Maintenance, primary therapy, Front-Line Platinum-Based
|Ovarian and Endometrial||Leap DEK-DKK1-P204
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer
Keywords: Epithelial Ovarian Cancer, Epithelial Endometrial Cancer, High-Grade Serous, Low-Grade Serous, Mucinous, Endometrioid, Clear Cell, Undifferentiated or Unclassified, DKN-01, Recurrent
A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
Keywords: Randomized, Cediranib, Olaparib, Ovarian, Platinum Resistant
A Phase I/II STUDY OF Ruxolitinib With Front-Line Neoadjuvant And Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Keywords: Ruxolitinib, Neoadjuvant, Epithelial Ovarian
A Phase 2 Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
Keywords: Ovarian Cancer, Clear Cell, Recurrent, Persistent, Pembrolizumab and Epacadostat
|Ovarian||IIT-Uyar Merck 3475-250
Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer
Keywords: Suboptimal Cytoreduced, Ovarian, Pembrolizumab, First Line, Epithelial, Nonrandomized
|Ovarian and Endometrial||Sutro- STRO-002-GM1
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Keywords: Advance Epithelial Ovarian Cancer, Fallopian Tube, Primary Peritoneal and Endometrial Cancer, Folate Receptor Alpha
|Recurrent Platinum Sensitive Ovarian Cancer||Roche Y040482
A phase IB study of cobimetinib administered in combination with niraparib, with or without atezolizumab, to patients with advanced platinum-sensitive ovarian cancer
Keywords: Ovarian, Platinum Sensitive, Recurrent, Cobimetinib, Niraparib, Atezolizumab, Parp Inhibitor, Immunotherapy, Phase 1